New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 12, 2014
07:35 EDTPETXAratana Therapeutics initiates pivotal study for AT-001
Aratana Therapeutics announced the initiation of the pivotal field effectiveness study for AT-001, the company's innovative drug for treating pain in dogs with osteoarthritis. The randomized, blinded, multicenter pivotal study will enroll approximately 300 client-owned dogs with osteoarthritis, and will be conducted under a study protocol for which Aratana received concurrence from the FDA's Center for Veterinary Medicine. The primary endpoint will be a reduction in osteoarthritis pain compared to placebo, as indicated by the Canine Brief Pain Inventory scale, a well validated and widely used scoring system.
News For PETX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 13, 2014
08:06 EDTPETXAratana Therapeutics and Atopix complete global licensing agreement
Subscribe for More Information
October 10, 2014
19:27 EDTPETXAratana Therapeutics management to meet with Piper Jaffray
Subscribe for More Information
October 7, 2014
10:02 EDTPETXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
October 6, 2014
16:10 EDTPETXAratana Therapeutics initiated with an Overweight at Piper Jaffray
Target $17.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use